WO2002010453A3 - Molecular toxicology modeling - Google Patents

Molecular toxicology modeling Download PDF

Info

Publication number
WO2002010453A3
WO2002010453A3 PCT/US2001/023872 US0123872W WO0210453A3 WO 2002010453 A3 WO2002010453 A3 WO 2002010453A3 US 0123872 W US0123872 W US 0123872W WO 0210453 A3 WO0210453 A3 WO 0210453A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxicity
molecular toxicology
genes
toxin
modeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/023872
Other languages
French (fr)
Other versions
WO2002010453A2 (en
Inventor
Donna Mendrick
Mark W Porter
Kory R Johnson
Arthur L Castle
Michael R Elashoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Priority to CA002414421A priority Critical patent/CA2414421A1/en
Priority to AU2001280889A priority patent/AU2001280889A1/en
Priority to EP01959321A priority patent/EP1364049A2/en
Priority to JP2002516369A priority patent/JP2004522411A/en
Publication of WO2002010453A2 publication Critical patent/WO2002010453A2/en
Anticipated expiration legal-status Critical
Publication of WO2002010453A3 publication Critical patent/WO2002010453A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.
PCT/US2001/023872 2000-07-31 2001-07-30 Molecular toxicology modeling Ceased WO2002010453A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002414421A CA2414421A1 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling
AU2001280889A AU2001280889A1 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling
EP01959321A EP1364049A2 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling
JP2002516369A JP2004522411A (en) 2000-07-31 2001-07-30 Molecular toxicology modeling

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US22204000P 2000-07-31 2000-07-31
US60/222,040 2000-07-31
US24488000P 2000-11-02 2000-11-02
US60/244,880 2000-11-02
US29002901P 2001-05-11 2001-05-11
US60/290,029 2001-05-11
US29064501P 2001-05-15 2001-05-15
US60/290,645 2001-05-15
US29233601P 2001-05-22 2001-05-22
US60/292,336 2001-05-22
US29579801P 2001-06-06 2001-06-06
US60/295,798 2001-06-06
US29745701P 2001-06-13 2001-06-13
US60/297,457 2001-06-13
US29888401P 2001-06-19 2001-06-19
US60/298,884 2001-06-19
US30345901P 2001-07-09 2001-07-09
US60/303,459 2001-07-09

Publications (2)

Publication Number Publication Date
WO2002010453A2 WO2002010453A2 (en) 2002-02-07
WO2002010453A3 true WO2002010453A3 (en) 2003-08-14

Family

ID=27578706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023872 Ceased WO2002010453A2 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling

Country Status (6)

Country Link
US (2) US20020119462A1 (en)
EP (1) EP1364049A2 (en)
JP (2) JP2004522411A (en)
AU (1) AU2001280889A1 (en)
CA (1) CA2414421A1 (en)
WO (1) WO2002010453A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7921068B2 (en) * 1998-05-01 2011-04-05 Health Discovery Corporation Data mining platform for knowledge discovery from heterogeneous data types and/or heterogeneous data sources
WO2002103954A2 (en) * 2001-06-15 2002-12-27 Biowulf Technologies, Llc Data mining platform for bioinformatics and other knowledge discovery
US7444308B2 (en) * 2001-06-15 2008-10-28 Health Discovery Corporation Data mining platform for bioinformatics and other knowledge discovery
US7590493B2 (en) * 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP1392871A4 (en) * 2001-05-22 2006-04-19 Gene Logic Inc MOLECULAR TOXICOLOGY MODELING
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
US20070054269A1 (en) * 2001-07-10 2007-03-08 Mendrick Donna L Molecular cardiotoxicology modeling
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20050071088A1 (en) * 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
WO2003042857A1 (en) * 2001-11-01 2003-05-22 Gene Network Sciences, Inc. Network ingerence methods
JP2005525790A (en) * 2001-11-19 2005-09-02 プロテオロジックス，インク． Methods for identifying and validating potential drug targets
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
EP1476747A4 (en) * 2002-01-31 2008-06-11 Ocimum Biosolutions Inc Molecular hepatotoxicology modeling
US20040005547A1 (en) * 2002-03-14 2004-01-08 Franziska Boess Biomarkers and expression profiles for toxicology
EP1490076A4 (en) * 2002-03-11 2010-01-06 Lipomics Technologies Inc NEW METABOLIC TARGETS AND MARKERS
EP1344834A3 (en) * 2002-03-14 2004-06-02 F. Hoffmann-La Roche Ag Methods for the toxicity prediction of a compound
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003284921A1 (en) * 2002-10-22 2004-05-13 Iconix Pharmaceuticals, Inc. Reticulocyte depletion signatures
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
WO2004058957A2 (en) * 2002-12-31 2004-07-15 Pharmacia & Upjohn Company Llc Canine cyp1a2 sequences
US7853406B2 (en) * 2003-06-13 2010-12-14 Entelos, Inc. Predictive toxicology for biological systems
US20040260721A1 (en) * 2003-06-20 2004-12-23 Marie Coffin Methods and systems for creation of a coherence database
JP2007501617A (en) * 2003-08-07 2007-02-01 ジーン ロジック インコーポレイテッド Primary rat hepatotoxicity modeling
WO2005017807A2 (en) * 2003-08-13 2005-02-24 Iconix Pharmaceuticals, Inc. Apparatus and method for classifying multi-dimensional biological data
DE10342274B4 (en) * 2003-09-12 2007-11-15 Siemens Ag Identify pharmaceutical targets
DE10344345B3 (en) 2003-09-24 2005-05-12 Siemens Ag Method for communication in an ad hoc radio communication system
CA2546391A1 (en) * 2003-11-24 2005-06-09 Gene Logic, Inc. Methods for molecular toxicology modeling
JP4616178B2 (en) * 2003-11-27 2011-01-19 武田薬品工業株式会社 Drug toxicity prediction method
US20080281526A1 (en) * 2004-03-22 2008-11-13 Diggans James C Methods For Molecular Toxicology Modeling
CN100408695C (en) * 2004-03-31 2008-08-06 株式会社格诺切克 DNA chip for screening peroxisome proliferation
JP2007533005A (en) * 2004-04-07 2007-11-15 ジーン ロジック インコーポレイテッド Hepatotoxic molecular model
WO2005124650A2 (en) * 2004-06-10 2005-12-29 Iconix Pharmaceuticals, Inc. Sufficient and necessary reagent sets for chemogenomic analysis
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
WO2006008005A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)
US20060142233A1 (en) * 2004-11-09 2006-06-29 Ting-Kai Li Gene expression and genetic changes implicated in alcoholism
CN1920567B (en) * 2005-08-26 2012-01-04 中国科学院上海生命科学研究院 Application of hexulose (phosphokinase)
EP1767939A1 (en) * 2005-09-23 2007-03-28 F. Hoffmann-La Roche Ag FABP4 as marker for a toxic effect
US20070198653A1 (en) * 2005-12-30 2007-08-23 Kurt Jarnagin Systems and methods for remote computer-based analysis of user-provided chemogenomic data
US7467118B2 (en) 2006-01-12 2008-12-16 Entelos Inc. Adjusted sparse linear programming method for classifying multi-dimensional biological data
ES2300176B1 (en) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas METHOD FOR THE MOLECULAR PROSTATE CANCER DIAGNOSIS, KIT TO IMPLEMENT THE METHOD.
US11001881B2 (en) * 2006-08-24 2021-05-11 California Institute Of Technology Methods for detecting analytes
WO2008014485A2 (en) 2006-07-28 2008-01-31 California Institute Of Technology Multiplex q-pcr arrays
US11525156B2 (en) 2006-07-28 2022-12-13 California Institute Of Technology Multiplex Q-PCR arrays
US11560588B2 (en) 2006-08-24 2023-01-24 California Institute Of Technology Multiplex Q-PCR arrays
US20100021885A1 (en) * 2006-09-18 2010-01-28 Mark Fielden Reagent sets and gene signatures for non-genotoxic hepatocarcinogenicity
WO2009018492A2 (en) 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
CN102356162A (en) 2009-02-04 2012-02-15 得克萨斯系统大学董事会 Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
WO2013016226A1 (en) * 2011-07-22 2013-01-31 Metamark Genetics, Inc. Quality control method for digital pathology
JP6124498B2 (en) * 2011-07-29 2017-05-10 株式会社メディクローム Evaluation method of biotoxicity of chemical substances
CN102721814A (en) * 2011-11-16 2012-10-10 天津美德太平洋科技有限公司 F protein detection reagent and detection method therefor
US9846885B1 (en) * 2014-04-30 2017-12-19 Intuit Inc. Method and system for comparing commercial entities based on purchase patterns
ES2748117T3 (en) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnosis of a new autoimmune disease
JP2016104032A (en) * 2016-02-23 2016-06-09 株式会社メディクローム Evaluation method of chemical biotoxicity
WO2017155858A1 (en) 2016-03-07 2017-09-14 Insilixa, Inc. Nucleic acid sequence identification using solid-phase cyclic single base extension
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
EP3937780A4 (en) 2019-03-14 2022-12-07 InSilixa, Inc. METHODS AND SYSTEMS FOR TIME RESOLVED FLUORESCENCE-BASED DETECTION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012760A2 (en) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Toxicological response markers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0680517T4 (en) * 1993-01-21 2005-05-02 Harvard College Method and Diagnostic Kits to Determine the Toxicity of a Compound Using Mammalian Stress Promoters
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
CA2269669A1 (en) * 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO1999010536A1 (en) * 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
US6403778B1 (en) * 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6160105A (en) * 1998-10-13 2000-12-12 Incyte Pharmaceuticals, Inc. Monitoring toxicological responses
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
EP1137809A1 (en) * 1998-12-09 2001-10-04 Vistagen, Inc. Toxicity typing using embryoid bodies
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20010049139A1 (en) * 2000-03-23 2001-12-06 Eric Lagasse Hepatic regeneration from hematopoietic stem cells
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
US7993907B2 (en) * 2001-05-08 2011-08-09 Mowycal Lending, Llc Biochips and method of screening using drug induced gene and protein expression profiling
EP1397144A4 (en) * 2001-05-15 2005-02-16 Psychogenics Inc SYSTEMS AND METHODS FOR BEHAVIOR COMPUTING MONITORING
US6956233B2 (en) * 2002-08-26 2005-10-18 Sin-Etsu Chemical Co., Ltd. Plated substrate for hard disk medium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012760A2 (en) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Toxicological response markers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BISSIG MARCO ET AL: "Functional Expression Cloning of the Canalicular Sulfate Transport System of Rat Hepatocytes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 269, no. 4, 28 January 1994 (1994-01-28), pages 3017 - 3021, XP002190711, ISSN: 0021-9258 *
DATABASE GENBANK [online] NCBI; 12 April 1994 (1994-04-12), BISSIG ET AL.: "Rattus norvegicus sulfate anion-transporter (sat-1) mRNA", XP002219697, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. L23413 *
DATABASE GENBANK [online] NCBI; 26 January 1996 (1996-01-26), RABURN ET AL.: "Rattus norvegicus anti-proliferative factor (BTG1) mRNA", XP002219696, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. L26268 *
FARR S ET AL: "CONCISE REVIEW: GENE EXPRESSION APPLIED TO TOXICOLOGY", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, SAN DIEGO, FL,, US, vol. 50, no. 1, July 1999 (1999-07-01), pages 1 - 9, XP001096475, ISSN: 1096-6080 *
NUWAYSIR E F ET AL: "MICROARRAYS AND TOXICOLOGY: THE ADVENT OF TOXICOGENOMICS", MOLECULAR CARCINOGENESIS, ALAN LISS, NEW YORK, NY,, US, vol. 24, no. 3, March 1999 (1999-03-01), pages 153 - 159, XP001008421, ISSN: 0899-1987 *
RABURN DOUGLAS J ET AL: "Stage-specific expression of B cell translocation gene 1 in rat testis.", ENDOCRINOLOGY, vol. 136, no. 12, 1995, pages 5769 - 5777, XP002219695, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2002010453A2 (en) 2002-02-07
US20020119462A1 (en) 2002-08-29
EP1364049A2 (en) 2003-11-26
US20080215250A1 (en) 2008-09-04
AU2001280889A1 (en) 2002-02-13
CA2414421A1 (en) 2002-02-07
JP2008148706A (en) 2008-07-03
JP2004522411A (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2002010453A3 (en) Molecular toxicology modeling
WO2002095000A3 (en) Molecular toxicology modeling
WO2004048598A3 (en) Molecular nephrotoxicology modeling
WO2003064624A3 (en) Molecular hepatotoxicology modeling
WO2004063334A8 (en) Molecular cardiotoxicology modeling
Istifli et al. Cell division, cytotoxicity, and the assays used in the detection of cytotoxicity
WO2007016668A3 (en) Methods and compositions for disease prognosis based on nucleic acid methylation
WO2007084902A9 (en) Methods of determining relative genetic likelihoods of an individual matching a population
MXPA05008519A (en) Cotton event mon 88913 and compositions and methods for detection thereof.
WO2004053062A3 (en) Bentgrass event asr-368 and compositions and methods for detection thereof
WO2004059293A3 (en) Markers for differential diagnosis and methods of use thereof
EP1860186A3 (en) Method for distinguishing mesenchymal stem cells using different markers
Žegura et al. Microcystin-LR induced DNA damage in human peripheral blood lymphocytes
Bretherton et al. User‐controlled 4D biomaterial degradation with substrate‐selective sortase transpeptidases for single‐cell biology
WO2003068908A3 (en) Cardiotoxin molecular toxicology modeling
BRPI0413253A (en) method for identifying a soybean underline, set of markers useful for identifying a soybean plant, computer system and reading medium
Richter The place of the name in Deuteronomy
Prot et al. Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip
WO2005014793A3 (en) Primary rat hepatocyte toxicity modeling
WO2005067648A3 (en) Multiplex spatial profiling of gene expression
IL148615A0 (en) Genetic markers of toxicity, preparation and uses thereof
Herczeg et al. Distribution of Ablepharus kitaibelii fitzingeri Mertens, 1952 (Squamata: Scincidae) in Hungary
WO2004097005A3 (en) Global analysis of transposable elements as molecular markers of the developmental potential of stem cells
WO2006086748A3 (en) Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs
WO2005030924A3 (en) Genetic markers for skatole metabolism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2414421

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001959321

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002516369

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001959321

Country of ref document: EP